| Followers | 65 |
| Posts | 27738 |
| Boards Moderated | 0 |
| Alias Born | 11/23/2016 |
Thursday, December 20, 2018 6:32:12 AM
Nice work bio!
I do have one initial question/critique.
All the figures I can find support the fact that the prevalence of Alzheimer's is about twice as high in women versus men. It is also true that this magnitude difference cannot be explained simply by life expectancy or all sorts of other factors proposed and reviewed.e.g. not well understood.
Hence your thesis could well have merit, except what have been the means of contraception in different countries over time and did the pill have prevalence?
I suspect you have considered this, although my quick research is not all supportive.
The picture of contraceptive methods vary over time and by country. in Japan the pill has never been widely used and yet the prevalence there of AD is also higher among women than men.
Across all European countries the prevalence of AD in women is also consistently about twice that of men.
2013: The prevalence of dementia in Europe
However, we cannot conclude that the majority of women in all those countries would have used the pill in 1960's and 1970's. For example in predominantly Catholic countries birth control by the pill or otherwise is shall we say less common.
The use of the pill tailed off in the mid seventies across pretty much all countries and was complemented with a range of other contraceptive methods such that the pill now represents below 20% and of course now with far lower hormone content. If your thesis is true we should be seeing the prevalence of AD in women coming down.
I do have one initial question/critique.
All the figures I can find support the fact that the prevalence of Alzheimer's is about twice as high in women versus men. It is also true that this magnitude difference cannot be explained simply by life expectancy or all sorts of other factors proposed and reviewed.e.g. not well understood.
Hence your thesis could well have merit, except what have been the means of contraception in different countries over time and did the pill have prevalence?
I suspect you have considered this, although my quick research is not all supportive.
The picture of contraceptive methods vary over time and by country. in Japan the pill has never been widely used and yet the prevalence there of AD is also higher among women than men.
Across all European countries the prevalence of AD in women is also consistently about twice that of men.
2013: The prevalence of dementia in Europe
However, we cannot conclude that the majority of women in all those countries would have used the pill in 1960's and 1970's. For example in predominantly Catholic countries birth control by the pill or otherwise is shall we say less common.
The use of the pill tailed off in the mid seventies across pretty much all countries and was complemented with a range of other contraceptive methods such that the pill now represents below 20% and of course now with far lower hormone content. If your thesis is true we should be seeing the prevalence of AD in women coming down.
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
